USA flag logo/image

An Official Website of the United States Government

System for Rapid Generation of Aptamers for Transplant Therapies

Award Information

Agency:
Department of Health and Human Services
Branch:
N/A
Award ID:
95915
Program Year/Program:
2010 / SBIR
Agency Tracking Number:
CA150490
Solicitation Year:
N/A
Solicitation Topic Code:
NCI
Solicitation Number:
N/A
Small Business Information
CYNVENIO BIOSYSTEMS, INC.
2260 Townsgate Road WESTLAKE VILLAGE, CA 91361-2437
View profile »
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No
 
Phase 1
Fiscal Year: 2010
Title: System for Rapid Generation of Aptamers for Transplant Therapies
Agency: HHS
Contract: 1R43CA150490-01
Award Amount: $99,996.00
 

Abstract:

DESCRIPTION (provided by applicant): Autologous hematopoietic stem cell transplantation (HSCT) has been an important treatment option for many patients with hematologic malignancies and solid tumors such as acute myeloid leukemia, myelodysplastic syndromes , chronic myeloid leukemia, systemic mastocytosis and breast cancer. During the treatment, anti CD34 antibodies are used to enrich the CD34+ hematopoietic stem cells from mobilized peripheral blood, which are re-infused after a high-dose radio/chemotherapy . Unfortunately, due to the large sample volumes required to obtain sufficient number of stem cells (100-300 mL), the antibody reagents are prohibitively expensive, typically in excess of 10,000 per therapy. To address this problem, we propose to develop an alternate, nucleic acid-based affinity reagents (i.e. aptamers) against the CD34 antigen, which will be stable, exhibit high affinities and specificities, significantly less immunogenic, and considerably less expensive (~10X less) compared to protein-ba sed reagents. Toward this end, we propose three specific aims: first, in order to circumvent the traditional time-consuming and labor-intensive SELEX process, we will adopt and optimize our high throughput microfluidic aptamer discovery platform (Pro-SELEX ) to isolate high affinity aptamers (Kd lt 1 nM) for the CD34 antigen. The selection will be carried out using purified extracellular domain of the CD34 protein from mammalian cell expression system (Chinese Hamster Ovary cells) such that the structure an d post-translational modifications are conserved. Secondly, we note that the overwhelming reason for treatment failure is highly correlated to the degree of contamination of circulating tumor cells during the purification of CD34+ cells. Thus, in order to significantly raise the specificity of the aptamers against tumor cells, we will develop a novel, cell-surface counter selection process using live leukemia and other tumor cells. Finally, we will evaluate and compare the performance of the anti-CD34 apt amers with commercially available anti-CD34 antibodies. We will measure the binding efficiency and specificity to CD34+ cells with flow cytometry, and perform magnetic cell selection of spiked CD34+ cells in whole blood. If successful, the project will hav e significant ramifications because 1) it will significantly lower the cost of HSCT and, 2) it will advance the aptamer selection technology to rapidly generate high affinity aptamers against a wide range of cell surface markers, which have far-reaching ap plication in clinical diagnosis and therapies. PUBLIC HEALTH RELEVANCE: Autologous hematopoietic stem cell transplantation (HSCT) has served as an important treatment option for many patients with hematologic malignancies and solid tumors includin g acute myeloid leukemia, myelodysplastic syndromes, chronic myeloid leukemia, systemic mastocytosis and breast cancer. Unfortunately, the antibody-based reagents used in the therapy to isolate CD34+ hematopoietic stem cells remain prohibitively expensive (gt 10,000 per procedure). To address this issue, we aim to develop a novel system capable of rapidly generating aptamers, and utilize it to isolate high affinity aptamers that bind to the CD34 surface antigen. The success of this project has important ra mifications as it will significantly reduce the cost for many cell-based transplantation therapies, and also establish a universal method to generate high-affinity aptamers for a wide range of diagnostic and therapeutic applications.

Principal Investigator:

Karen Qian

Business Contact:

Paul Meyer
tsoh@cynvenio.com
Small Business Information at Submission:

CYNVENIO BIOSYSTEMS, INC.
2260 Townsgate Road Unit 2 Westlake Village, CA 91316

EIN/Tax ID: 127159223
DUNS: N/A
Number of Employees: N/A
Woman-Owned: No
Minority-Owned: No
HUBZone-Owned: No